SEROSTIM (somatropin) by Emergent BioSolutions is cells. First approved in 1996.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
SEROSTIM (somatropin) is a recombinant human growth hormone (GH) administered by injection that treats growth hormone deficiency (GHD) and related conditions by binding to GH receptors on target cells, triggering intracellular signaling that induces production of IGF-1 and other anabolic proteins. The drug stimulates skeletal growth, protein synthesis, and metabolic effects in pediatric and adult patients. Somatropin has been approved for nearly three decades and remains the standard-of-care GH replacement therapy.
Product approaching loss of exclusivity with $107M annual Part D spend, suggesting moderate brand team size focused on transition planning and managed care retention.
cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or effects mediated indirectly by IGF-1,…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Worked on SEROSTIM at Emergent BioSolutions? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$107M Medicare spend — this is a commercially significant brand
SEROSTIM offers stable career opportunities in a mature biologic franchise with strong brand equity and established reimbursement, though limited new trial activity. Professionals joining now should anticipate a transition phase focused on market defense, biosimilar preparation, and managed care strategy rather than growth-stage innovation.